Janssen Biotech Inc.

Janssen Biotech Inc. is a global pharmaceutical and biotechnology company headquartered in Horsham, Pennsylvania, with additional facilities in California, Massachusetts, and the Netherlands. It was founded in 1979 as Centocor Biotech, Inc., with an initial focus on developing diagnostic assays using monoclonal antibody technology. In 2011, Centocor Ortho Biotech changed its name to Janssen Biotech, Inc. as part of a global effort to unite the Janssen Pharmaceutical Companies under a common identity. Janssen Biotech Inc. operates as a wholly-owned subsidiary of Johnson & Johnson. In September 2023, the broader Janssen Pharmaceutical Companies of Johnson & Johnson began a rebranding effort to become Johnson & Johnson Innovative Medicine, though the Janssen name continues to be used for specific entities like Janssen Biotech Inc. The company has approximately 72 to 200 employees.

Janssen Biotech Inc. develops, manufactures, and markets innovative medications and treatments across five key therapeutic areas: oncology, immunology, neuroscience, infectious diseases, and cardiovascular and metabolic diseases. Notable products include cancer drugs like Imbruvica and Darzalex, and the immunology drug Stelara. The company also engages in co-development agreements, such as for cancer drug candidates targeting B-cell malignant tumors, and utilizes RNA-targeting technology for autoimmune disorders.

In terms of patent litigation, Janssen Biotech Inc. appears to operate as a defensive litigant. The company has one tracked case, in which it is listed as a defendant in a proceeding before the Patent Trial and Appeal Board (PTAB), initiated on March 27, 2026. This posture, with zero plaintiff cases and one defendant case, is characteristic of an operating company defending its intellectual property or challenging the validity of patents asserted against it.

The single tracked case, "Unknown Petitioner v. Janssen Biotech Inc." before the Patent Trial and Appeal Board, indicates that Janssen Biotech Inc. is currently involved in a challenge to a patent, likely as a patent owner defending its patent against a third-party petition for inter partes review (IPR) or post-grant review (PGR).